Patents by Inventor Raju Mohan

Raju Mohan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plasma Carboxypeptidase B Inhibitors
    Publication number: 20110319366
    Abstract: Compounds of the following formula (I), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
    Type: Application
    Filed: August 29, 2011
    Publication date: December 29, 2011
    Inventors: Brad Buckman, Kumar Emayan, Imadul Islam, Karen May, Judi Bryant, Raju Mohan, Christopher West, Shendong Yuan
  • Pyrrole Derivatives As Pharmaceutical Agents
    Publication number: 20110301128
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: August 22, 2011
    Publication date: December 8, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lynne Canne Bannen, Jeff Chen, Lisa Esther Dalrymple, Brenton T. Flatt, Timothy Patrick Forsyth, Xiao-Hui Gu, Morrison B. Mac, Larry W. Mann, Grace Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C. Stevens, Tie-Lin Wang, Yong Wang, Jason H. Wu
  • 1-Phenylpyrrole Derivatives
    Publication number: 20110263544
    Abstract: The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1-C3 alkyl group; R2 represents a hydroxy-C1-C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1-C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like, —R5 represents a sulfamoyl group or a C1-C3 alkylsulfonyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.
    Type: Application
    Filed: October 7, 2009
    Publication date: October 27, 2011
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, EXELIXIS, INC.
    Inventors: John Nuss, Matthew Williams, Raju Mohan, Richard Martin, Tie-Lin Wang, Hiroyuki Tsuruoka, Kazumasa Aoki, Masatoshi Honzumi, Yusuke Asoh, Keiji Saito, Tsuyoshi Homma
  • Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives
    Publication number: 20110263673
    Abstract: The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases. The compound is an atropisomer of a compound represented by the following general formula (I): wherein R1 represents a C1-C3 alkyl group; R2 represents a 2-hydroxy-C4-C6 alkyl group; R3 represents a halogeno group, a halogeno-C1-C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like; R5 represents a C1-C3 alkyl group; and R6 represents a hydrogen atom, a halogeno group and the like] or atropisomers thereof.
    Type: Application
    Filed: October 7, 2009
    Publication date: October 27, 2011
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, EXELIXIS, INC.
    Inventors: John Nuss, Matthew Williams, Raju Mohan, Richard Martin, Tie-Lin Wang, Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Tsuyoshi Homma
  • Pyrrole derivatives as pharmaceutical agents
    Patent number: 8026237
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Grant
    Filed: July 30, 2005
    Date of Patent: September 27, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lynne Canne Bannen, Jeff Chen, Lisa Esther Dalrymple, Brenton T Flatt, Timothy Patrick Forsyth, Xiao-Hui Gu, Morrison B Mac, Larry W Mann, Grace Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C Stevens, Tie-Lin Wang, Yong Wang, Jason H Wu
  • Modulators of LXR
    Patent number: 8013001
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Haixia Wang, Yinong Xie
  • Plasma carboxypeptidase B inhibitors
    Patent number: 8008325
    Abstract: Compounds of the following formula (I), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: August 30, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Brad O. Buckman, Kumar Emayan, Imadul Islam, Karen May, Judi Bryant, Raju Mohan, Christopher West, Shendong Yuan
  • Modulators of LXR
    Patent number: 7998986
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 16, 2011
    Assignee: Exelixis Patent Company LLC
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Ronald C. Griffith
  • LXR and FXR modulators
    Patent number: 7998995
    Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 16, 2011
    Assignee: Exelixis Patent Company LLC
    Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
  • Benzylthiazolone inhibitors of estrogen-related receptors (ERR)
    Patent number: 7977489
    Abstract: Compounds of the following general structure for use in compositions and methods for modulating the activity of nuclear receptors are provided: The compounds are useable in compositions and methods for modulating the estrogen related receptors and are agonists, partial agonists, antagonists. or inverse agonists of ERR or ERR?.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: July 12, 2011
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Raju Mohan, Brett B. Busch, Michael Charles Nyman, William C. Stevens, Jr.
  • Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands
    Publication number: 20110144128
    Abstract: Heterocyclic carboxamide compounds are described herein as being useful in modulating the activity of steroid nuclear receptors. Pharmaceutical compositions containing the compounds, methods of using the compounds and processes for making the compounds are also described.
    Type: Application
    Filed: January 6, 2006
    Publication date: June 16, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Brenton T. Flatt, Xiao-Hui Gu, Richard Martin, Raju Mohan, Brett Murphy, Michael C. Nyman, William C. Stevens, JR., Tie-Lin Wang
  • Bridged ring structures as pharmaceutical agents
    Patent number: 7863298
    Abstract: The present invention is directed to 1?,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the vitamin D receptor using an effective amount of a compound of formula (I).
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: January 4, 2011
    Assignee: Exelixis, Inc.
    Inventors: Brenton T. Flatt, Richard Martin, Raju Mohan, Brett Murphy
  • MODULATORS OF LXR
    Publication number: 20100331295
    Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: June 26, 2006
    Publication date: December 30, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett B Busch, Brenton T. Flatt, Xiao Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, JR., Tie Lin Wang, Yinong Xie
  • Azepinoindole Derivatives As Pharmaceutical Agents
    Publication number: 20100173824
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: August 4, 2009
    Publication date: July 8, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett Busch, Brenton T. Flatt, Xiao-Hui Gu, Richard Martin, Raju Mohan, Tie-Lin Wang, Jason H. Wu
  • 11 BETA-HSD1 MODULATORS
    Publication number: 20100105675
    Abstract: A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2009
    Publication date: April 29, 2010
    Applicant: Exelixis, Inc.
    Inventors: Richard Martin, Brenton Flatt, Jackline Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie Lin Wang
  • IMIDAZOLE BASED LXR MODULATORS
    Publication number: 20100075964
    Abstract: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: June 26, 2006
    Publication date: March 25, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao-Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • LXR and FXR Modulators
    Publication number: 20100069367
    Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 7, 2007
    Publication date: March 18, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Brant Clayton Boren, Brett B. Busch, Xiao-Hui Gu, Vasu Jammalamadaka, Shao Po Lu, Richard Martin, Raju Mohan, Edwin Schweiger, William C. Stevens, Tie-Lin Wang, Yinong Xie, Wei Xu
  • Modulators of LXR
    Publication number: 20100056582
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 17, 2008
    Publication date: March 4, 2010
    Applicant: X-CEPTOR THERAPEUTICS, INC.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, JR., Haixia Wang, Yinong Xie
  • 11 Beta-HSD1 Modulators
    Publication number: 20090247515
    Abstract: A compound according to Formula A: or a pharmaceutically acceptable salt thereof, wherein R11, G1 and G2 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2009
    Publication date: October 1, 2009
    Applicant: Exelixis, Inc.
    Inventors: Richard Martin, Brenton T. Flatt, Jackline Eve Dalgard, Venkataiah Bollu, Ping Huang, Raju Mohan, Edwin Schweiger, Tie-Lin Wang
  • Azepinoindole derivatives as pharmaceutical agents
    Patent number: 7595311
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: September 29, 2009
    Assignee: Exelixis, Inc.
    Inventors: Brett Busch, Brenton T Flatt, Xiao-Hui Gu, Richard Martin, Raju Mohan, Tie-Lin Wang, Jason H Wu